MARKSANS / FY26 summary

The year in one view.

Marksans Pharma · annual summary assembled from the available FY26 source records.

Research layer active

Revenue across quarters

2,330.8

₹ Cr where applicable

PAT across quarters

361.8

₹ Cr where applicable

Source quarters

3

₹ Cr where applicable

EBITDA (₹ Cr)PositiveWatchNegative
3 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q2 FY26: 144.5 · Positive source sentiment · 2025-10-30Q2 FY26Q3 FY26: 160.7 · Positive source sentimentQ3 FY26Q4 FY26: 601 · Positive source sentimentQ4 FY26601144.5
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.